CF PharmTech

IPO

长风药业股份有限公司 - 长风药业股份有限公司

Public · China · $140.0M raised

Business Model
B2B
Total Funding
$140.0M
Last Round
$50.0M Series FJun 2020
Rounds
2
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

CF PharmTech (长风药业, HKEx: 2652.HK) is a China-based publicly listed biopharmaceutical company specializing in inhaled drug delivery formulations. The company focuses on developing and manufacturing inhalation products including dry powder inhalers, nebulizer solutions, nasal sprays, liposomes, and pressurized metered-dose inhalers (pMDIs). CF PharmTech serves patients across respiratory and systemic therapeutic areas, providing innovative inhalation drug delivery technologies for conditions including asthma, COPD, and allergic rhinitis.

Summary

CF PharmTech is a Biotech company based in China. It has raised $140.0M in total across 2 rounds, most recently a $50.0M Series F round in Jun 2020. Investors include BioTrack Capital, China Capital Investment Group and New Alliance Capital.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOOct 2025

Sign up to see all 3 events

Funding: Series E through Series F. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

CF PharmTech on Indexed.vc
<a href="https://indexed.vc/companies/cf-pharmtech"><img src="https://indexed.vc/api/badge/company/cf-pharmtech" alt="CF PharmTech on Indexed.vc" width="260" height="76" /></a>